Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply…

Psyence reports major breakthrough in establishing pharmaceutical-grade ibogaine supply - BioTuesdays

Psyence BioMedical (NASDAQ: BPM) has announced it has sourced a sustainable supply of high-potency iboga bark—through its strategic partner, closely held PsyLabs—a significant achievement as the company prepares for the clinical development of nature-derived ibogaine for substance use disorders. According to Psyence, the collaboration with PsyLabs is an important step in securing a long-term supply of high-quality active pharmaceutical ingredien…